Monitor the company's response to the USFDA and any subsequent regulatory action (e.g., warning letter, import alert) that could affect API supply or revenue from the Mexico facility. The two observations are not detailed, so the risk is currently low but warrants tracking for escalation.
RDY drugs
RDY drug pipeline →How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Sep 14 $11.91entry
- T+1 · 2mo ago −3.02%α −2.56% · $11.55
- T+5 · due 8w ago Pending
- T+20 · due 5w ago Pending
- T+45 · todayOpen
- T+60 · in 21d Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Dr. Reddy's disclosed that the USFDA completed a records assessment at its API manufacturing facility in Mexico (Jiutepec, Morelos) between July 17 and September 8, 2026, issuing a Form FDA 2953 with two observations. The company will respond within the stipulated timeline. This is a routine regulatory follow-up with no material financial impact disclosed, and the two observations are not quantified or characterized as critical.
Key Facts
- USFDA conducted a records assessment under Section 704(a)(4) at Dr. Reddy's API facility in Mexico (Industrias Químicas Falcón de México, S.A. de C.V.) from July 17 to September 8, 2026.
- The USFDA issued a Form FDA 2953 containing two observations; the company will respond within the stipulated timeline.
- No warning letter, shutdown, import alert, or material financial impact was disclosed in the filing.
Financial Impact
No financial figures disclosed; two observations from a records assessment with no indication of material cost or revenue impact.
Risk Factors
- Potential escalation to a warning letter or import alert if the USFDA deems the response inadequate, which could disrupt API production and sales.
- Uncertainty around the nature of the two observations, if they relate to data integrity or quality systems, remediation costs could be material.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 6-K Filing (Primary) | 0001575872-26-000646 |
| Document: 0001575872-26-000646-index.html | 0001575872-26-000646 |
| Document: 0001575872-26-000646.txt | 0001575872-26-000646 |
Track record
73 reports on RDY
7 of 12 bullish or bearish reports moved the stock their way by T+5. Best: +23.28% at T+20 after the Jun 26, 2026 report. 7 of 12 went positive at some point.
Filters
- Nov 16, 2026today 6-K Bullish 4/10 Entry $14.85 Now $14.70 −1.01% settles Nov 23
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $14.86 Now $14.70 −1.08% settles Nov 17
- Nov 9, 20267d ago Institutional Cluster Neutral 3/10 Entry $15.05 to $14.70 Now $14.70 −2.33% ▼ −2.33% −0.63% vs SPY
- Nov 5, 202611d ago 6-K Neutral 4/10 Entry $14.53 to $14.73 Now $14.70 +1.17% ▲ +1.38% −1.91% vs SPY
- Nov 4, 202612d ago 6-K Neutral 2/10 Entry $14.77 to $14.84 Now $14.70 −0.47% ▲ +0.47% +1.39% vs SPY
- Nov 2, 202614d ago 144 Bearish 5/10 Entry $14.13 to $15.05 Now $14.70 −4.03% ▼ −6.51% −6.43% vs SPY
- Oct 29, 202618d ago 6-K Neutral 2/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 28, 202619d ago 6-K Neutral 3/10 Entry $14.11 to $14.53 Now $14.70 +4.18% ▲ +2.98% +7.70% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
- Oct 26, 202621d ago 6-K Neutral 2/10 Entry $13.75 to $14.17 Now $14.70 +6.91% ▲ +3.05% +4.32% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers